Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Zomedica Corp. | exh_991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2020
| ZOMEDICA PHARMACEUTICALS CORP. |
| (Exact name of registrant as specified in its charter) |
| Alberta, Canada | 001-38298 | N/A |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
| 100 Phoenix Drive, Suite 180, Ann Arbor, Michigan | 48108 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (734) 369-2555
| Not Applicable |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| □ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| □ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| □ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| □ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Shares, without par value | ZOM | NYSE American |
Item 8.01. Other Events.
On March 13, 2020, the Board of Directors of Zomedica Pharmaceuticals Corp. (the “Company”) authorized the adoption of an Amended and Restated Stock Option Plan (the “Amended and Restated Plan”), which effected certain immaterial amendments to the Company’s Stock Option Plan (the “Original Plan”).
The Amended and Restated Plan clarifies that: (i) the Company may grant stock options directors, officers, consultants or employees of the subsidiaries of the Company, (ii) any stock option granted thereunder shall have a maximum term of ten years and (iii) the Company may effect required tax withholdings, including by withholding a number of common shares otherwise issuable upon the exercise of an option and selling such shares to satisfy the withholding obligation. All material terms of the Amended and Restated Plan remain the same as previously disclosed in connection with the Original Plan. The Amended and Restated Plan became effective on the date of adoption by the Board of Directors.
The Amended and Restated Plan is filed herewith as Exhibit 99.1, and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description |
| 99.1 | Amended and Restated Stock Option Plan |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZOMEDICA PHARMACEUTICALS CORP. | |||
| Date: March 17, 2020 | By: | /s/ Shameze Rampertab | |
| Name: Shameze Rampertab | |||
| Title: Chief Financial Officer | |||